AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21272417 — intervention group
Group type: COMPARATOR
Intervention: Usual care from general practitioners (GP-UC)
Number of subjects: 341
Study 19961603 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy, corticosteroid injection, and naproxen
Number of subjects: 0
Study 19961603 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy, placebo injection, and naproxen
Number of subjects: 0
Study 19961603 — intervention group
Group type: COMPARATOR
Intervention: Wait and see treatment with naproxen alone
Number of subjects: 0
Study 17143826 — intervention group
Group type: EXPERIMENTAL
Intervention: usZDV/sdNVP
Number of subjects: 609
Study 17143826 — intervention group
Group type: COMPARATOR
Intervention: sdNVP
Number of subjects: 609
Study 15128682 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical treatment with omeprazole and serological H.pylori testing
Number of subjects: 199
Study 15128682 — intervention group
Group type: COMPARATOR
Intervention: Prompt upper gastrointestinal endoscopy
Number of subjects: 199
Study 15128682 — intervention group
Group type: COMPARATOR
Intervention: Prompt upper gastrointestinal radiography
Number of subjects: 199
Study 12028831 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive selection (CD34 selection alone)
Number of subjects: 101
Study 12028831 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive/negative selection (CD34 selection followed by breast cancer cell depletion)
Number of subjects: 101
Study 9566670 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone (average 6.0+/−0.2 mg daily)
Number of subjects: 19
Study 8313822 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (150 mg)
Number of subjects: 0
Study 8313822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8313822 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (12 micrograms/kg)
Number of subjects: 0
Study 3417465 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group with access to PEFR information
Number of subjects: 30
Study 3417465 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 29301556 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 72
Study 26566091 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous chest compressions at a rate of 120 min−1 with asynchronous ventilations (CCaV-120)
Number of subjects: 17
Study 26566091 — intervention group
Group type: COMPARATOR
Intervention: 3:1 chest compression to ventilation (C:V) ratio
Number of subjects: 17
Study 24751173 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaches who attended 2 coach education sessions
Number of subjects: 80
Study 24751173 — intervention group
Group type: COMPARATOR
Intervention: No treatment control (coaches who did not receive coach education sessions)
Number of subjects: 80
Study 23517933 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab induction (160/80 mg)
Number of subjects: 0
Study 23517933 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab maintenance (40 mg every-other-week)
Number of subjects: 0
Study 23517933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22319691 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-antibiotic
Number of subjects: 82
Study 22319691 — intervention group
Group type: COMPARATOR
Intervention: 10% Ichthammol glycerine pack
Number of subjects: 82
Study 18466276 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave disinfection (650 W for 6 min, three times per week for 30 days)
Number of subjects: 60
Study 18466276 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave disinfection + topical miconazole (three times per day for 30 days)
Number of subjects: 60
Study 18466276 — intervention group
Group type: COMPARATOR
Intervention: Topical miconazole (three times per day for 30 days)
Number of subjects: 60
Study 18466276 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine denture care)
Number of subjects: 60
Study 18466276 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave disinfection
Number of subjects: 60
Study 17460558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (n=31)
Number of subjects: 61
Study 17460558 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (n=30)
Number of subjects: 61
Study 12963662 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparoscopic cholecystectomy (MLC)
Number of subjects: 90
Study 12963662 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 90
Study 12963662 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mm laparoscopic cholecystectomy (5-mm LC)
Number of subjects: 90
Study 10960945 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (200 mg/m2 i.v. 3-hour infusion on day 1) + Carboplatin (AUC 6)
Number of subjects: 127
Study 10960945 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (200 mg/m2 i.v. 3-hour infusion on day 1) + Gemcitabine (1,000 mg/m2 on days 1 and 8)
Number of subjects: 127
Study 9376155 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered budesonide
Number of subjects: 66
Study 9376155 — intervention group
Group type: COMPARATOR
Intervention: Standard aerosol
Number of subjects: 66
Study 8159877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin and clindamycin
Number of subjects: 42
Study 8159877 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 42
Study 2419693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pafenolol 50 mg once daily
Number of subjects: 23
Study 2419693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pafenolol 100 mg once daily
Number of subjects: 23
Study 2419693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30365470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion at 10°C for 10 minutes
Number of subjects: 30
Study 30365470 — intervention group
Group type: COMPARATOR
Intervention: Control (no cold-water immersion)
Number of subjects: 30
Study 25376194 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine Extended Release (GXR)
Number of subjects: 29
Study 25376194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 27444425 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment (Motivational Enhancement Therapy and Prolonged Exposure delivered concurrently)
Number of subjects: 183
Study 27444425 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment (Motivational Enhancement Therapy and Prolonged Exposure delivered sequentially)
Number of subjects: 183
Study 25261164 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (25 μg/d)
Number of subjects: 251
Study 25261164 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (10 μg/d)
Number of subjects: 251
Study 25261164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 22589439 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular color fundus photography (CFP) hyperpigmentation
Number of subjects: 314
Study 22589439 — intervention group
Group type: EXPERIMENTAL
Intervention: CFP hyperpigmentation in 20 study eyes
Number of subjects: 314
Study 22589439 — intervention group
Group type: EXPERIMENTAL
Intervention: SDOCT regions with hyperreflective foci in another subset of 20 eyes
Number of subjects: 314
Study 20543019 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional therapy plus proprioceptive neuromuscular facilitation plus neuromobilization (Experimental group 2)
Number of subjects: 96
Study 20543019 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional therapy plus proprioceptive neuromuscular facilitation (Experimental group 1)
Number of subjects: 96
Study 20543019 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy (Control group)
Number of subjects: 96
Study 19115912 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg/day (125 mg bid)
Number of subjects: 44
Study 19115912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 15825909 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A Behavior Pattern assessment using the Jenkins Activity Survey, Form H
Number of subjects: 200
Study 15825909 — intervention group
Group type: COMPARATOR
Intervention: Control group (no history of psychiatric sick-leaves)
Number of subjects: 200
Study 12939216 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg on alternate days)
Number of subjects: 22071
Study 12939216 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs (1 to 59 days/year)
Number of subjects: 22071
Study 12939216 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs (≥60 days/year)
Number of subjects: 22071
Study 12939216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study 10376499 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ambulation after diagnostic cardiac catheterization
Number of subjects: 0
Study 10376499 — intervention group
Group type: COMPARATOR
Intervention: Standard care (not explicitly mentioned)
Number of subjects: 0
Study 8664135 — intervention group
Group type: EXPERIMENTAL
Intervention: New Patient Information Package (NPIP)
Number of subjects: 304
Study 8664135 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini version of the same package (mini‐NPIP)
Number of subjects: 304
Study 8664135 — intervention group
Group type: COMPARATOR
Intervention: No information package (Control)
Number of subjects: 304
Study 1738766 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Smart environmental intervention including a school lunch program providing cardiovascular healthful food choices, reduced in fat by 30% and in sodium and sugar by 50%; physical education program promoting personal fitness and aerobic conditioning; cardiovascular risk factor screening.
Number of subjects: 0
Study 1738766 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Smart environmental intervention (school lunch program).
Number of subjects: 0
Study 1738766 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Smart environmental intervention (physical education program).
Number of subjects: 0
Study 1738766 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Smart environmental intervention (overall program).
Number of subjects: 0
Study 6383614 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term drug therapy (cyclophosphamide)
Number of subjects: 461
Study 6383614 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term drug therapy (cyclophosphamide)
Number of subjects: 461
Study 6383614 — intervention group
Group type: COMPARATOR
Intervention: No drug therapy
Number of subjects: 461
Study 31860203 — intervention group
Group type: COMPARATOR
Intervention: Standard low-calorie diet (1730 kcal, protein - 87.4 g, fat - 61.4 g, carbohydrates - 207 g)
Number of subjects: 50
Study 31860203 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized diet (2125 kcal, protein - 100.2 g, fat - 75.9 g, carbohydrates - 260 g) with modification of protein component
Number of subjects: 50
Study 29069507 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab (30, 100 or 150 mg)
Number of subjects: 305
Study 29069507 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab (150 mg)
Number of subjects: 305
Study 29069507 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab
Number of subjects: 305
Study 29069507 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 305
Study 26549249 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 1255
Study 26549249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1255
Study 24589826 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First intervention
Number of subjects: 60
Study 24589826 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual
Number of subjects: 60
Study 22457372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative visits and counselling by ICU nurses
Number of subjects: 120
Study 22457372 — intervention group
Group type: COMPARATOR
Intervention: Routine pre-operative counselling by surgeons only (Control)
Number of subjects: 120
Study 19580457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive bisphosphonate therapy
Number of subjects: 1324
Study 19580457 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 1324
Study 19227421 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal presence during anesthesia induction (Group M)
Number of subjects: 100
Study 19227421 — intervention group
Group type: COMPARATOR
Intervention: Maternal absence during anesthesia induction (Group C)
Number of subjects: 100
Study 19227421 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group M and Group C)
Number of subjects: 100
Study 16376757 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-triggered (DT) acquisition
Number of subjects: 20
Study 16376757 — intervention group
Group type: COMPARATOR
Intervention: Continuous imaging (CIM)
Number of subjects: 20
Study 11890871 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 0
Study 11890871 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic management
Number of subjects: 0
Study 9472182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium plus albuterol (initial dose of albuterol 2.5 mg followed by 2 more doses at 20-min intervals, ipratropium 0.5 mg combined with the initial dose of albuterol)
Number of subjects: 55
Study 9472182 — intervention group
Group type: COMPARATOR
Intervention: Albuterol alone (2.5 mg initial dose followed by 2 more doses at 20-min intervals)
Number of subjects: 55
Study 8585220 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobe-Mugos (tablets)
Number of subjects: 59
Study 8585220 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobe-Mugos (dragees)
Number of subjects: 59
Study 8585220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 2504075 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.4 mg/kg) and Innovar (0.04 ml/kg)
Number of subjects: 36
Study 2504075 — intervention group
Group type: COMPARATOR
Intervention: Chlorprothixene (2.0 mg/kg)
Number of subjects: 36
Study 1091393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital 60 mg
Number of subjects: 0
Study 1091393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital 180 mg
Number of subjects: 0
Study 1091393 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 0
Study 1091393 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 150 mg
Number of subjects: 0
Study 1091393 — intervention group
Group type: EXPERIMENTAL
Intervention: Methapyrilene 50 mg
Number of subjects: 0
Study 1091393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital 100 mg
Number of subjects: 0
Study 1091393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31337369 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on age, location of carcinoma, tumor grade, TNM stage, size of carcinoma, lymph node ratio (LNR)
Number of subjects: 6341
Study 31337369 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram-predicted probability score (≥20, 10-19 and <10)
Number of subjects: 6341
Study 28049480 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy rehabilitation program with coaching based on cognitive behavioral therapy (CBT) principles (OTc)
Number of subjects: 288
Study 28049480 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor monitoring added to the occupational therapy intervention (OTcsm)
Number of subjects: 288
Study 28049480 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 288
Study 25847578 — intervention group
Group type: EXPERIMENTAL
Intervention: tMBSR
Number of subjects: 63
Study 25847578 — intervention group
Group type: COMPARATOR
Intervention: tSupport
Number of subjects: 63
Study 23632670 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion (ABT)
Number of subjects: 204
Study 23632670 — intervention group
Group type: COMPARATOR
Intervention: No-drainage
Number of subjects: 204
Study 21321491 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-4 diaminopyridine (DAP)
Number of subjects: 20
Study 21321491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19016463 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band blue-light therapy
Number of subjects: 30
Study 19016463 — intervention group
Group type: COMPARATOR
Intervention: Red-light therapy (control)
Number of subjects: 30
Study 16510061 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 0
Study 16510061 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (Protonix)
Number of subjects: 0
Study 16510061 — intervention group
Group type: EXPERIMENTAL
Intervention: H2RAs or PPIs (maintenance therapy)
Number of subjects: 0
Study 16510061 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery
Number of subjects: 0
Study 16510061 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper endoscopy
Number of subjects: 0
Study 16510061 — intervention group
Group type: EXPERIMENTAL
Intervention: PPIs as a class
Number of subjects: 0
Study 10553391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ignition interlock program
Number of subjects: 1387
Study 10553391 — intervention group
Group type: COMPARATOR
Intervention: Conventional postlicensing treatment program (control)
Number of subjects: 1387
Study 10553391 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-interlock period (after unrestricted driving privileges were returned)
Number of subjects: 1387
Study 8552800 — intervention group
Group type: EXPERIMENTAL
Intervention: Concrete objective information based on self‐regulation theory
Number of subjects: 62
Study 8552800 — intervention group
Group type: COMPARATOR
Intervention: Self‐care instruction
Number of subjects: 62
Study 1913768 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish
Number of subjects: 11
Study 1913768 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% chlorhexidine varnish
Number of subjects: 11
Study 1913768 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% chlorhexidine varnish
Number of subjects: 11
Study 1913768 — intervention group
Group type: EXPERIMENTAL
Intervention: 0% chlorhexidine varnish
Number of subjects: 11
Study 1913768 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish (removed after 15 min)
Number of subjects: 11
Study 1913768 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish (left on for 8 h)
Number of subjects: 11
Study 6412733 — intervention group
Group type: EXPERIMENTAL
Intervention: Alaproclate alone
Number of subjects: 6
Study 6412733 — intervention group
Group type: EXPERIMENTAL
Intervention: Alaproclate combined with morphine
Number of subjects: 6
Study 6412733 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine i.v.
Number of subjects: 6
Study 6412733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30516574 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 112
Study 30516574 — intervention group
Group type: COMPARATOR
Intervention: Mirtazapine (30 mg/d)
Number of subjects: 112
Study 29726282 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lozenges containing Lactobacillus reuteri
Number of subjects: 10
Study 29726282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 26198895 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 248
Study 26198895 — intervention group
Group type: COMPARATOR
Intervention: Conventional monopolar electrosurgery
Number of subjects: 248
Study 24536008 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SLC)
Number of subjects: 117
Study 23224449 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 22
Study 23224449 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 22
Study 19944452 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with paclitaxel and carboplatin (58% underwent three cycles, 42% had six cycles)
Number of subjects: 74
Study 19944452 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with paclitaxel and carboplatin
Number of subjects: 74
Study 17442119 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf muscle stretching and sham ultrasound (n = 46)
Number of subjects: 92
Study 17442119 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound alone (n = 46)
Number of subjects: 92
Study 16082607 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-dose aprotinin (500.000 KIU [70 mg] in the pump)
Number of subjects: 86
Study 16082607 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 86
Study 11852741 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week problem-solving diabetes education program
Number of subjects: 53
Study 11852741 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 53
Study 10223359 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with 2 g cefotaxime
Number of subjects: 347
Study 10223359 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with 4g piperacillin plus 0.5g tazobactam
Number of subjects: 347
Study 10223359 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (control group)
Number of subjects: 347
Study 7495071 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 2,500 IU
Number of subjects: 20
Study 7495071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin 7,500 IU
Number of subjects: 20
Study 7495071 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg
Number of subjects: 20
Study 7495071 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg
Number of subjects: 20
Study 2086399 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) with laser ridge
Number of subjects: 100
Study 2086399 — intervention group
Group type: COMPARATOR
Intervention: Intraocular lens (IOL) without laser ridge
Number of subjects: 100
Study 31529385 — intervention group
Group type: EXPERIMENTAL
Intervention: CR + TM
Number of subjects: 56